HDL—is it too big to fail? (original) (raw)

• Friedewald, V. E. Jr, Ballantyne, C. M., Davidson, M. H., Guyton, J. R. & Roberts, W. C. The editor's roundtable: lipid management beyond statins—reducing residual cardiovascular risk. Am. J. Cardiol 102, 559–567 (2008).
  Article Google Scholar
• Brewer, H. B. Jr. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J. Clin. Endocrinol. Metab. 96, 1246–1257 (2011).
  Article CAS Google Scholar
• Barter, P. HDL-C: role as a risk modifier. Atheroscler. Suppl. 12, 267–270 (2011).
  Article CAS Google Scholar
• Emerging Risk Factors Collaboration et al. Lipid-related markers and cardiovascular disease prediction. JAMA 307, 2499–2506 (2012).
• Barter, P. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301–1310 (2007).
  Article CAS Google Scholar
• Rosenson, R. S. et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125, 1905–1919 (2012).
  Article Google Scholar
• Alwaili, K., Awan, Z., Alshahrani, A. & Genest, J. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev. Cardiovasc. Ther. 8, 413–423 (2010).
  Article CAS Google Scholar
• Vucic, E. & Rosenson, R. S. Recombinant high-density lipoprotein formulations. Curr. Atheroscler Rep. 13, 81–87 (2011).
  Article CAS Google Scholar
• Tabet, F. & Rye, K. A. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci. (Lond.) 116, 87–98 (2009).
  Article CAS Google Scholar
• Joy, T. & Hegele, R. A. Is raising HDL a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7, 143–155 (2008).
  Article CAS Google Scholar
• Duffy, D. & Rader, D. J. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6, 455–463 (2009).
  Article Google Scholar
• Asztalos, B. F., Tani, M. & Schaefer, E. J. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol. 22, 176–185 (2011).
  Article CAS Google Scholar
• Vaisar, T. et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117, 746–756 (2007).
  Article CAS Google Scholar
• Mackness, B. & Mackness, M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol. 660, 143–151 (2010).
  Article CAS Google Scholar
• Soran, H., Hama, S., Yadav, R. & Durrington, P. N. HDL functionality. Curr. Opin. Lipidol. 23, 353–366 (2012).
  Article CAS Google Scholar
• Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127–135 (2011).
  Article CAS Google Scholar
• de la Llera-Moya, M. et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30, 796–801 (2010).
  Article CAS Google Scholar
• Degoma, E. M. & Rader, D. J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 8, 266–277 (2011).
  Article CAS Google Scholar
• Tardif, J. C., Heinonen, T. & Noble, S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr. Atheroscler. Rep. 11, 58–63 (2009).
  Article CAS Google Scholar
• Calabresi, L., Simonelli, S., Gomaraschi, M. & Franceschini, G. Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 222, 299–306 (2012).
  Article CAS Google Scholar
• Iatan, I., Palmyre, A., Alrasheed, S., Ruel, I. & Genest, J. Genetics of cholesterol efflux. Curr. Atheroscler. Rep. 14, 235–246 (2012).
  Article CAS Google Scholar
• Ng, D. S. et al. Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics. Arterioscler. Thromb. Vasc Biol. 15, 2157–2164 (1995).
  Article CAS Google Scholar
• Tietjen, I. et al. Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim. Biophys. Acta 1821, 416–424 (2012).
  Article CAS Google Scholar
• Oliveira, H. C. & de Faria, E. C. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life 63, 248–257 (2011).
  Article CAS Google Scholar
• Vergeer, M. et al. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med. 364, 136–145 (2011).
  Article CAS Google Scholar
• Hegele, R. A. et al. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. 13, 720–728 (1993).
  Article CAS Google Scholar
• Frikke-Schmidt, R. et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299, 2524–2532 (2008).
  Article CAS Google Scholar
• Johannsen, T. H. et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J. Clin. Endocrinol. Metab. 94, 1264–1273 (2009).
  Article CAS Google Scholar
• Haase, C. L. et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J. Clin. Endocrinol. Metab. 97, E248–E256 (2012).
  Article CAS Google Scholar
• Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012).
  Article CAS Google Scholar
• Canner, P. L. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245–1255 (1986).
  Article CAS Google Scholar
• Frick, M. H. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237–1245 (1987).
  Article CAS Google Scholar
• Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410–418 (1999).
  Article CAS Google Scholar
• ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).
• AIM-HIGH Investigators et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255–2267 (2011).
• Goldenberg, I. et al. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch. Intern. Med. 169, 508–514 (2009).
  Article CAS Google Scholar
• Jun, M. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875–1884 (2010).
  Article CAS Google Scholar
• Merck. Merck announces HPS2-THRIVE study of Tredaptive™ (Extended-Release Niacin/Laropiprant) did not achieve primary endpoint [online] (2012).
• Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T. & Wang, N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7, 365–375 (2008).
  Article CAS Google Scholar
• Hewing, B. & Fisher, E. A. Rationale for cholesteryl ester transfer protein inhibition. Curr. Opin. Lipidol. 23, 372–376 (2012).
  Article CAS Google Scholar
• Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
  Article CAS Google Scholar
• Hu, X. et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150, 2211–2219 (2009).
  Article CAS Google Scholar
• Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007).
  Article CAS Google Scholar
• Vergeer, M. et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118, 2515–2522 (2008).
  Article CAS Google Scholar
• Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J. C. & Nissen, S. E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118, 2506–2514 (2008).
  Article CAS Google Scholar
• Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755–1766 (2012).
  Article CAS Google Scholar
• Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
  Article CAS Google Scholar
• Hooper, A. J. & Burnett, J. R. Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin. Investig. Drugs 21, 1427–1432 (2012).
  Article CAS Google Scholar
• Niesor, E. J. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr. Opin. Lipidol. 22, 288–295 (2011).
  Article CAS Google Scholar